<em>NEIL3</em> contributes toward the carcinogenesis of liver cancer and regulates PI3K/Akt/mTOR signaling

Wang,Weichen; Yin,Qing; Guo,Shanshan; Wang,Jun

doi:10.3892/etm.2021.10487

NEIL3 contributes toward the carcinogenesis of liver cancer and regulates PI3K/Akt/mTOR signaling

Authors:
- Weichen Wang
- Qing Yin
- Shanshan Guo
- Jun Wang
View Affiliations

Affiliations: Medical Research and Laboratory Diagnostic Center, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China, Department of Medical Education, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China, Department of Food Science and Nutrition, University of Jinan, Jinan, Shandong 250022, P.R. China
Published online on: July 23, 2021 https://doi.org/10.3892/etm.2021.10487
Article Number: 1053
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver cancer is one of the top three fatal types of cancer and it causes several thousands of mortalities each year. The main treatment is surgical resection which shows little benefit for patients with recurrence or metastasis. NEIL3 promotes progression and predicts survival in cancer. However, its role in liver cancer remains unclear. Based on data in the TCGA database, NEIL3 exhibited much higher expression in liver cancer tissues and was clinically correlated with tumor grade in patients with liver cancer. Furthermore, high NEIL3 expression caused shorter survival times. In liver cancer cell lines, NEIL3 showed abundant expression. When NEIL3 was knocked down in HepG2 and Huh‑7 cells, cell abilities including proliferation, growth, migration and invasion, exhibited deficiency to different extents. Cell cycle transition was blocked at the G2 phase and the cell apoptotic rate increased notably. In addition, the phosphorylation levels of Akt, PI3K and mTOR were increased following NEIL3‑overexpression but decreased following NEIL3‑knockdown. In conclusion, NEIL3 contributes toward development and/or progression in liver cancer and regulates PI3K/Akt/mTOR signaling.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
2	Liu CY, Chen KF and Chen PJ: Treatment of liver cancer. Cold Spring Harb Perspect Med. 5(a021535)2015.PubMed/NCBI View Article : Google Scholar
3	Li L and Wang H: Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 379:191–197. 2016.PubMed/NCBI View Article : Google Scholar
4	Marin JJG, Cives-Losada C, Asensio M, Lozano E, Briz O and Macias RIR: Mechanisms of anticancer drug resistance in hepatoblastoma. Cancer (Basel). 11(407)2019.PubMed/NCBI View Article : Google Scholar
5	Keating GM: Sorafenib: A review in hepatocellular carcinoma. Target Oncol. 12:243–253. 2017.PubMed/NCBI View Article : Google Scholar
6	Zhu YJ, Zheng B, Wang HY and Chen L: New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 38:614–622. 2017.PubMed/NCBI View Article : Google Scholar
7	Liu MM, Bandaru V, Bond JP, Jaruga P, Zhao X, Christov PP, Burrows CJ, Rizzo CJ, Dizdaroglu M and Wallace SS: The mouse ortholog of NEIL3 is a functional DNA glycosylase in vitro and in vivo. Proc Natl Acad Sci USA. 107:4925–4930. 2010.PubMed/NCBI View Article : Google Scholar
8	Bandaru V, Sunkara S, Wallace SS and Bond JP: A novel human DNA glycosylase that removes oxidative DNA damage and is homologous to Escherichia coli endonuclease VIII. DNA Repair (Amst). 1:517–529. 2002.PubMed/NCBI View Article : Google Scholar
9	Liu M, Doublie S and Wallace SS: Neil3, the final frontier for the DNA glycosylases that recognize oxidative damage. Mutat Res. 743-7444–11. 2013.PubMed/NCBI View Article : Google Scholar
10	Jalland CM, Scheffler K, Benestad SL, Moldal T, Ersdal C, Gunnes G, Suganthan R, Bjørås M and Tranulis MA: Neil3 induced neurogenesis protects against prion disease during the clinical phase. Sci Rep. 6(37844)2016.PubMed/NCBI View Article : Google Scholar
11	Sejersted Y, Hildrestrand GA, Kunke D, Rolseth V, Krokeide SZ, Neurauter CG, Suganthan R, Atneosen-Åsegg M, Fleming AM, Saugstad OD, et al: Endonuclease VIII-like 3 (Neil3) DNA glycosylase promotes neurogenesis induced by hypoxia-ischemia. Proc Natl Acad Sci USA. 108:18802–18807. 2011.PubMed/NCBI View Article : Google Scholar
12	Regnell CE, Hildrestrand GA, Sejersted Y, Medin T, Moldestad O, Rolseth V, Krokeide SZ, Suganthan R, Luna L, Bjørås M and Bergersen LH: Hippocampal adult neurogenesis is maintained by Neil3-dependent repair of oxidative DNA lesions in neural progenitor cells. Cell Rep. 2:503–510. 2012.PubMed/NCBI View Article : Google Scholar
13	Skarpengland T, Holm S, Scheffler K, Gregersen I, Dahl TB, Suganthan R, Segers FM, Østlie I, Otten JJ, Luna L, et al: Neil3-dependent base excision repair regulates lipid metabolism and prevents atherosclerosis in Apoe-deficient mice. Sci Rep. 6(28337)2016.PubMed/NCBI View Article : Google Scholar
14	Yang LX, Zhang X and Zhao G: Ginsenoside Rd attenuates DNA damage by increasing expression of DNA glycosylase endonuclease VIII-like proteins after focal cerebral ischemia. Chin Med J (Engl). 129:1955–1962. 2016.PubMed/NCBI View Article : Google Scholar
15	Massaad MJ, Zhou J, Tsuchimoto D, Chou J, Jabara H, Janssen E, Glauzy S, Olson BG, Morbach H, Ohsumi TK, et al: Deficiency of base excision repair enzyme NEIL3 drives increased predisposition to autoimmunity. J Clin Invest. 126:4219–4236. 2016.PubMed/NCBI View Article : Google Scholar
16	Smatlikova P, Askeland G, Vaskovicova M, Klima J, Motlik J, Eide L and Ellederová Z: Age-related oxidative changes in primary porcine fibroblasts expressing mutated huntingtin. Neurodegener Dis. 19:22–34. 2019.PubMed/NCBI View Article : Google Scholar
17	Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, Stec E, Ferrer M, Strulovici B, Hazuda DJ and Espeseth AS: Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe. 4:495–504. 2008.PubMed/NCBI View Article : Google Scholar
18	Shinmura K, Kato H, Kawanishi Y, Igarashi H, Goto M, Tao H, Inoue Y, Nakamura S, Misawa K, Mineta H and Sugimura H: Abnormal expressions of DNA glycosylase genes NEIL1, NEIL2, and NEIL3 are associated with somatic mutation loads in human cancer. Oxid Med Cell Longev. 2016(1546392)2016.PubMed/NCBI View Article : Google Scholar
19	Kim YS, Kim Y, Choi JW, Oh HE and Lee JH: Genetic variants and risk of prostate cancer using pathway analysis of a genome-wide association study. Neoplasma. 63:629–634. 2016.PubMed/NCBI View Article : Google Scholar
20	Klattenhoff AW, Thakur M, Chu CS, Ray D, Habib SL and Kidane D: Loss of NEIL3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to ATR inhibitor in glioblastoma cells. Oncotarget. 8:112942–112958. 2017.PubMed/NCBI View Article : Google Scholar
21	Jiraskova K, Hughes DJ, Brezina S, Gumpenberger T, Veskrnova V, Buchler T, Schneiderova M, Levy M, Liska V, Vodenkova S, et al: Functional polymorphisms in DNA repair genes are associated with sporadic colorectal cancer susceptibility and clinical outcome. Int J Mol Sci. 20(97)2018.PubMed/NCBI View Article : Google Scholar
22	de Sousa JF, Torrieri R, Searfim RB, Di Cristofaro LF, Escanfella DF, Ribeiro R, Zanette DL, Paçó-Larson ML, da Silva WA Jr, Tirapelli DP, et al: Expression signatures of DNA repair genes correlate with survival prognosis of astrocytoma patients. Tumour Biol. 39(1010428317694552)2017.PubMed/NCBI View Article : Google Scholar
23	Matta J, Morales L, Dutil J, Bayona M, Alvarez C and Suarez E: Differential expression of DNA repair genes in Hispanic women with breast cancer. Mol Cancer Biol. 1(54)2013.PubMed/NCBI View Article : Google Scholar
24	Nwani NG, Condello S, Wang Y, Swetzig WM, Barber E, Hurley T and Matei D: A novel ALDH1A1 inhibitor targets cells with stem cell characteristics in ovarian cancer. Cancers (Basel). 11(502)2019.PubMed/NCBI View Article : Google Scholar
25	Barry KH, Koutros S, Berndt SI, Andreotti G, Hoppin JA, Sandler DP, Burdette LA, Yeager M, Freeman LE, Lubin JH, et al: Genetic variation in base excision repair pathway genes, pesticide exposure, and prostate cancer risk. Environ Health Perspect. 119:1726–1732. 2011.PubMed/NCBI View Article : Google Scholar
26	Zhou J, Chan J, Lambele M, Yusufzai T, Stumpff J, Opresko PL, Thali M and Wallace SS: NEIL3 repairs telomere damage during S phase to secure chromosome segregation at mitosis. Cell Rep. 20:2044–2056. 2017.PubMed/NCBI View Article : Google Scholar
27	McNally EJ, Luncsford PJ and Armanios M: Long telomeres and cancer risk: The price of cellular immortality. J Clin Invest. 130:3474–3481. 2019.PubMed/NCBI View Article : Google Scholar
28	Chen X, Tang WJ, Shi JB, Liu MM and Liu XH: Therapeutic strategies for targeting telomerase in cancer. Med Res Rev. 40:532–585. 2020.PubMed/NCBI View Article : Google Scholar
29	Zhang H, Ma H, Wang Q, Chen M, Weng D, Wang H, Zhou J, Li Y, Sun J, Chen Y, et al: Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinoma using high-throughput SNP array. Oncol Rep. 23:445–455. 2010.PubMed/NCBI
30	Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, et al: Short tanderm repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA. 98:8012–8017. 2001.PubMed/NCBI View Article : Google Scholar
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
32	Bland JM and Altman DG: Survival probabilities (the Kaplan-Meier method). BMJ. 317(1572)1998.PubMed/NCBI View Article : Google Scholar
33	Tran OT, Tadesse S, Chu C and Kidane D: Overexpression of NEIL3 associated with altered genome and poor survival in selected types of human cancer. Tumour Biol. 42(1010428320918404)2020.PubMed/NCBI View Article : Google Scholar
34	Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, et al: Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 48:500–509. 2016.PubMed/NCBI View Article : Google Scholar
35	Ma G, Yang X, Liang Y, Wang L, Li D, Chen Y, Liang Z, Wang Y and Niu H: Precision medicine and bladder cancer heterogeneity. Bull Cancer. 105:925–931. 2018.PubMed/NCBI View Article : Google Scholar
36	Constantinidou A, Alifieris C and Trafalis DT: Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy. Pharmacol Ther. 194:84–106. 2019.PubMed/NCBI View Article : Google Scholar
37	Tella SH, Mahipal A, Kommalapati A and Jin Z: Evaluating the safety and efficacy of Nivolumab in patients with advanced hepatocellular carcinoma: Evidence to date. Onco Targets Ther. 12:10335–10342. 2019.PubMed/NCBI View Article : Google Scholar
38	Blum A, Wang P and Zenklusen JC: SnapShot: TCGA-analyzed tumors. Cell. 173(530)2018.PubMed/NCBI View Article : Google Scholar
39	Fouad YA and Aanei C: Revisiting the hallmarks of cancer. Am J Cancer Res. 7:1016–1036. 2017.PubMed/NCBI
40	Ribatti D: A revisited concept: Contact inhibition of growth. From cell biology to malignancy. Exp Cell Res. 359:17–19. 2017.PubMed/NCBI View Article : Google Scholar
41	Barnum KJ and Q'Connell MJ: Cell cycle regulation by checkpoints. Methods Mol Biol. 1170:29–40. 2014.PubMed/NCBI View Article : Google Scholar
42	Wenzel ES and Singh ATK: Cell-cycle checkpoints and aneuploidy on the path to cancer. In Vivo. 32:1–5. 2018.PubMed/NCBI View Article : Google Scholar
43	Tuzlak S, Kaufmann T and Villunger A: Interrogating the relevance of mitochondrial apoptosis for vertebrate development and postnatal tissue homeostasis. Genes Dev. 30:2133–2151. 2016.PubMed/NCBI View Article : Google Scholar
44	Goldar S, Khaniani MS, Derakhshan SM and Baradaran B: Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 16:2129–2144. 2015.PubMed/NCBI View Article : Google Scholar
45	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006.PubMed/NCBI View Article : Google Scholar
46	Czech MP: PIP2 and PIP3: Complex roles at the cell surface. Cell. 100:603–606. 2000.PubMed/NCBI View Article : Google Scholar
47	Dowling RJ, Topisirovic I, Fonseca DB and Sonenberg N: Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochim Biophys Acta. 1804:433–439. 2010.PubMed/NCBI View Article : Google Scholar
48	Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 18:1926–1945. 2014.PubMed/NCBI View Article : Google Scholar
49	Chen QY and Costa M: PI3K/Akt/mTOR signaling pathway and the biphasic effect of arsenic in carcinogenesis. Mol Pharmacol. 94:784–792. 2018.PubMed/NCBI View Article : Google Scholar
50	Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E and Wang L: PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 7:33440–33450. 2016.PubMed/NCBI View Article : Google Scholar
51	Kattan SW, Nafie MS, Elmgeed GA, Alelwani W, Badar M and Tantawy MA: Molecular docking, anti-proliferative activity and induction of apoptosis in human liver cancer cells treated with androstane derivatives: Implication of PI3K/AKT/mTOR pathway. J Steroid Biochem Mol Biol. 198(105604)2020.PubMed/NCBI View Article : Google Scholar